ATRC
Atricure Inc

389
Mkt Cap
$1.81B
Volume
512,024.00
52W High
$43.11
52W Low
$28.27
PE Ratio
-47.42
ATRC Fundamentals
Price
$36.47
Prev Close
$37.54
Open
$37.93
50D MA
$36.09
Beta
1.10
Avg. Volume
436,700.29
EPS (Annual)
-$0.9517
P/B
3.90
Rev/Employee
$357,928.46
Loading...
Loading...
News
all
press releases
AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management...
Business Wire·1h ago
News Placeholder
More News
News Placeholder
AtriCure to Participate in Upcoming Investor Conferences
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...
Business Wire·1d ago
News Placeholder
AtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·3mo ago
News Placeholder
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of +86.67% and +4.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Abbott (ABT) Q2 Earnings and Revenues Top Estimates
Abbott (ABT) delivered earnings and revenue surprises of +0.80% and +0.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
Here is how Amneal Pharmaceuticals (AMRX) and AtriCure (ATRC) have performed compared to their sector so far this year.
Zacks·4mo ago
News Placeholder
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Zacks·5mo ago
News Placeholder
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
Zacks·5mo ago
News Placeholder
Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect?
Zacks·6mo ago
News Placeholder
Why Barclays sees a buying opportuntiy in MedTech stocks
Investing.com -- Barclays said in a note Monday that it sees attractive entry points in MedTech stocks, as recent weakness in some sector leaders has created a buying opportunity despite the group’s strong year-to-date performance.
investing.com·7mo ago

Latest ATRC News

View

Advertisement|Remove ads.

Advertisement|Remove ads.